SPI Infoamtion

1. Analyst View

2. Research Methodology

3. Indian Generics Market - An Overview

4. Key Market Drivers
4.1 Increasing Export
4.2 Private Investments
4.3 Patent Expiries
4.4 Increasing Acceptance of Generics

5. Industry Performance
5.1 Market Size and Growth
5.2 Branded and Generics

6. Opportunities for Indian Generics Companies
6.1 US
6.2 Europe
6.3 Japan
6.4 African Countries

7. Emerging Industry Trends

8. Regulatory Environment

9. Industry Restraints and Recommendations
9.1 Counterfeit Drugs
9.2 Lack of Government Initiatives
9.3 Quality Issues

10. Competitive Landscape
10.1 Industry Structure
10.2 Key Deals & M&As
10.3 Key Players
10.3.1 Ranbaxy
10.3.2 Cipla Ltd.
10.3.3 Jubilant Organosys
10.3.4 Sun Pharmaceuticals
10.3.5 Zydus Cadila
10.3.6 Dr. Reddy’s Laboratories
10.3.7 Lupin Ltd.
10.3.8 Aurobindo Pharma
10.3.9 Glenmark Pharma
10.3.10 Piramal Healthcare

List of Figures:
Figure 4-1: Drugs and Pharmaceutical Export (Billion INR), 2004-05 to 2008-09
Figure 5-1: Pharmaceutical Market (Billion INR), FY 2009 to FY 2013
Figure 5-2: Generics Drug Market (Billion INR), FY 2009 to FY 2013
Figure 5-3: Share of Generics in Pharmaceutical Market (FY 2010)

List of Tables:
Table 4-1: Blockbuster Drugs Going Off-patent Globally (2010 to 2012)
Table 10-1: Key M&As in Indian Pharma Industry
Table 10-2: Ranbaxy Laboratories Ltd. - Strengths and Weaknesses
Table 10-3: Cipla Ltd. - Strengths and Weaknesses
Table 10-4: Jubilant Organosys - Strengths and Weaknesses
Table 10-5: Sun Pharmaceuticals - Strengths and Weaknesses
Table 10-6: Zydus Cadila - Strengths and Weaknesses
Table 10-7: Dr. Reddy’s Laboratories - Strengths and Weaknesses
Table 10-8: Lupin Ltd. - Strengths and Weaknesses
Table 10-9: Aurobindo Pharma - Strengths and Weaknesses
Table 10-10: Glenmark Pharma - Strengths and Weaknesses
Table 10-11: Piramal Healthcare - Strengths and Weaknesses